International medical experts have made a public statement rejecting studies that linked a diabetes drug to an increased risk of cancer . The experts were convened by pharmaceutical company Sanofi-Aventis .
Researchers called for more detailed analysis, following four studies published in journal Diabetologia last week. The authors had examined registers of diabetics throughout Europen, and linked Lantus with a greater risk of cancer .
At this stage, public bodies are thought to be examining the data further. The Sanofi panel, some of whom have financial links with the company – made it clear that there is not a link. The company are fighting to avoid a further fall in share prices and a decline in prescriptions of lantus.
The next stage may well be a review of the data, which Sanofi offered to fund. They reportedly said: “We are ready to implement the proposed plan of action, but we first need to have it endorsed by the appropriate bodies, including experts, before initiation of the proposed studies.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…